By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Zymeworks 

540 – 1385 West 8th Avenue

Vancouver  British Columbia  V6H 3V9  Canada
Phone: 604-678-1388 Fax: 604-737-7077


SEARCH JOBS

Established in 2003 with offices in Vancouver, BC and Seattle, WA, Zymeworks is a fast-growing, clinical-stage biotechnology company dedicated to the research, development and commercialization of best-in-class therapeutic bispecific antibodies and antibody drug conjugates for the treatment of cancer and autoimmune diseases. Zymeworks is proud to have active collaborations with Merck, Eli Lilly, Celgene, GlaxoSmithKline, and Daiichi-Sankyo is committed to making a meaningful difference in the lives of patients everywhere.

Zymeworks has received multiple Canadian awards for innovation including British Columbia’s “Emerging Life Sciences Company of the Year” in 2013 and BIOTECanada’s “Gold Leaf Emerging Company of the Year” award in 2015. Most recently, Zymeworks was named the “Life Sciences Company of the Year” for 2016 by LifeSciences BC, and was the recipient of BIOTECanada’s “Gold Leaf Biotech Company of the Year” award in 2016.


Key Statistics


Email: info@zymeworks.com
Ownership: Private

Web Site: Zymeworks
Employees:
Symbol: 
 









Company News
Zymeworks Submits ZW25 Phase 1 Clinical Study Findings Abstract For ASCO 2017 2/23/2017 6:58:20 AM
Zymeworks Receives Second Orphan Drug Designation For ZW25 In Gastric Cancer 2/16/2017 6:38:38 AM
Zymeworks Appoints Dr. Kenneth Hillan And Hollings Renton To Its Board Of Directors 2/14/2017 6:28:29 AM
Zymeworks Release: Biopharma Opens Up R&D Shop in Vancouver 1/25/2017 5:31:34 AM
Zymeworks Announces The Successful Achievement Of A Research Milestone With Eli Lilly (LLY) In Bispecific Antibody Collaboration 1/5/2017 11:16:41 AM
Zymeworks Announces The Addition Of Lota S. Zoth To Its Board Of Directors 11/22/2016 10:37:12 AM
Zymeworks And Daiichi Sankyo Announce Immuno-Oncology Cross-Licensing Agreement And Bi-Specific Antibody Collaboration 9/28/2016 8:10:51 AM
Zymeworks Doses First Patient In Phase I Trial Of ZW25, A Novel Bi-Specific Antibody For The Treatment Of HER2-Expressing Cancers 9/15/2016 11:40:33 AM
Zymeworks Receives FDA Acceptance Of IND Application For ZW25, A Novel Bi-Specific Antibody, For The Treatment Of HER2-Expressing Cancers 8/18/2016 9:29:49 AM
Zymeworks’ ZW25 And ZW33 Granted Orphan Drug Designation for Ovarian Cancer By U.S. FDA 8/18/2016 9:27:53 AM
12345
//-->